Industry
Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Loading...
Open
3.13
Mkt cap
85M
Volume
309K
High
3.23
P/E Ratio
-3.38
52-wk high
5.86
Low
3.08
Div yield
N/A
52-wk low
2.45
Portfolio Pulse from Benzinga Newsdesk
December 07, 2023 | 10:35 am
Portfolio Pulse from Charles Gross
December 07, 2023 | 12:11 am
Portfolio Pulse from Vandana Singh
November 14, 2023 | 7:08 pm
Portfolio Pulse from Benzinga Newsdesk
November 14, 2023 | 5:47 pm
Portfolio Pulse from totan@benzinga.com
November 09, 2023 | 9:49 pm
Portfolio Pulse from Benzinga Insights
November 08, 2023 | 7:01 pm
Portfolio Pulse from Benzinga Newsdesk
November 07, 2023 | 1:35 pm
Portfolio Pulse from Lisa Levin
October 17, 2023 | 12:12 pm
Portfolio Pulse from Benzinga Newsdesk
October 16, 2023 | 8:33 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.